Kidney cancer surgery often determined by surgeons' practice style, not medical factors

Mar 10, 2008

A new study reveals that the type of surgery a patient with kidney cancer receives depends more on the surgeon’s preference than on the patient’s tumor size, demographic characteristics, or general medical health. The findings indicate that patients with kidney cancer often may not be receiving the most appropriate surgical care. The study is published in the April 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

Open radical nephrectomy is the standard surgical treatment for patients with localized kidney cancer, but partial nephrectomy and laparoscopic surgery have emerged as attractive alternatives that are less invasive but equally effective. However, many physicians have not adopted these surgical techniques despite their benefits.

To investigate the potential barriers to adoption of partial nephrectomy and renal laparoscopy, David Miller, MD of the University of California Los Angeles and colleagues reviewed data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) program and the Centers for Medicare and Medicaid Services (CMS). They identified 5,483 Medicare beneficiaries diagnosed between 1997 and 2002 with localized kidney cancer, determined the type of surgery received by each patient, and identified the primary surgeon for each case.

The researchers assessed the use of radical nephrectomy, partial nephrectomy, and laparoscopy among these patients, noting surgeon- and patient-based factors that may have contributed to decisions about which type of surgery was used. A total of 611 patients underwent partial nephrectomies and 4,872 underwent radical nephrectomies, 515 of which were performed laparoscopically. After taking into consideration factors including patient demographics, comorbidity, tumor size, and volume of surgeries done by each surgeon, there was considerable variation among surgeons in the type of surgery they performed—an 18.1% variance for partial nephrectomy and a 37.4% variance for laparoscopy. Factors based on surgeons’ practice style contributed more to these variances than did patient characteristics.

The authors concluded that “for many older patients with kidney cancer, the surgery provided may depend more on their surgeon’s practice style than on the characteristics of the patient and his or her disease.” They added that “the timely dismantling of residual barriers to surgeons’ adoption of partial nephrectomy and laparoscopy is an important step toward improving the quality of care provided to patients with kidney cancer.”

Source: Wiley

Explore further: Merck drug Keytruda effective against 3 cancers

Related Stories

Iran poses growing cyber threat to US: study

19 minutes ago

Iran poses a growing threat to America's computer networks and has launched increasingly sophisticated digital attacks and spying on US targets, according to a new report released Thursday.

Humans can't resist those puppy-dog eyes

38 minutes ago

(HealthDay)—When humans and their four-legged, furry best friends look into one another's eyes, there is biological evidence that their bond strengthens, researchers report.

Roundworm parasite targets canine eyes

39 minutes ago

(HealthDay)—A small number of dogs and cats across the United States have been infected by a roundworm parasite that targets the eye, according to a new report.

Diversity is key to stability, grassland study finds

48 minutes ago

Biological diversity brings beauty and variety to our lives and to the world around us. It also could be the key to keeping ecosystems strong, according to a new University of Minnesota study published April 17 in the journal ...

Giant galaxies die from the inside out

58 minutes ago

A major astrophysical mystery has centred on how massive, quiescent elliptical galaxies, common in the modern Universe, quenched their once furious rates of star formation. Such colossal galaxies, often also ...

Recommended for you

Merck drug Keytruda effective against 3 cancers

2 hours ago

One of the hot new cancer immunotherapy drugs, Merck & Co.'s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer ...

DNA blood test detects lung cancer mutations

Apr 17, 2015

Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.